Immunize.org supports evidence-based vaccination recommendations and schedules. Read more at About Us.

Ask the Experts: RSV (Respiratory Syncytial Virus): Vaccine Recommendations during Pregnancy

Results (12)


1:17

View All Video Questions

Last reviewed: December 6, 2024

The American College of Obstetricians and Gynecologists (ACOG) and CDC recommend that previously unvaccinated pregnant patients between 32 and 36 weeks and 6 days’ gestation get one dose of the Pfizer RSVpreF vaccine (Abrysvo) to protect their babies during their first RSV season after birth. Only Abrysvo is FDA-approved and recommended for pregnant patients. Arexvy (GSK) and mResvia (Moderna) are not approved and should not be given during pregnancy.

CDC recommends vaccination during the months of September through January in most of the continental United States while ACOG recommends vaccination as an option from September 1 through March 1; the September 2026 AAP schedule and current the American Academy of Family Physicians (AAFP) guidance use this extended window.

ACOG’s rationale for extending the option of using vaccine was based on recent RSV seasons extending longer into the spring. However, it is not possible to predict local RSV activity at the time of birth when vaccinating a woman up to 8 weeks before delivery. RSV preventive antibody products administered at the time of birth, if available and acceptable to the parent, have the advantage of providing immediate protection if RSV remains a late season threat. However, if the mother is unvaccinated and RSV is not circulating locally at the time of delivery, then protection with an RSV preventive antibody can be deferred and delivered in the fall before the onset of the infant’s first full RSV season. If, however, the mother was vaccinated and RSV circulation is not a threat by the time of delivery, then the infant would not be eligible for RSV preventive antibody in the fall when RSV begins to circulate again. For late season RSV protection, use of preventive antibody products allows more precise timing of protection.

Those who provide health care to pregnant patients who live in areas with different patterns of RSV seasonality, such as Alaska, Hawaii, parts of Florida, or other jurisdictions outside the continental United States, should follow guidance from state or territorial public health authorities about the timing of RSV vaccination during pregnancy in their regions.

ACOG and CDC recommend only a single maternal RSV vaccine dose; they do not recommend revaccination during subsequent pregnancies. However, RSV vaccination during one pregnancy is not expected to protect infants resulting from future pregnancies. Therefore, a patient who is currently pregnant and received RSV vaccine before the current pregnancy should be counseled to immunize their infant with an RSV preventive antibody for protection against RSV disease after birth.

See CDC guidance (www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/pregnant-people.html) and ACOG’s practice advisory (www.acog.org/clinical/guidance/practice-advisory/2023/09/maternal-respiratory-syncytial-virus-vaccination).

Last reviewed: November 8, 2026

The main difference is seasonal timing. The American College of Obstetricians and Gynecologists (ACOG) recommends maternal Abrysvo from September 1 through March 1 in most of the continental United States; CDC’s current window remains September 1 through January 31. Both use 32 weeks 0 days through 36 weeks 6 days’ gestation and do not recommend repeat maternal vaccination in a later pregnancy.

ACOG’s rationale for extending the option of using vaccine until March was based on recent RSV seasons extending longer into the spring. However, in February it is not possible to predict local RSV activity at the time of birth when vaccinating a woman up to 8 weeks before delivery. RSV preventive antibody products, if available and acceptable to the parent, have the advantage of providing immediate protection (or deferral) based on the actual RSV circulation conditions at the time of delivery. If the mother is unvaccinated and RSV is no longer circulating locally, then protection with an RSV preventive antibody can be delivered in the fall before the onset of the infant’s first full RSV season. If, however, RSV circulation is no longer an issue by the time of delivery, and the mother was vaccinated, then the infant would not be eligible for RSV preventive antibody in the fall when RSV begins to circulate again. For late season RSV protection in February, although ACOG maintains vaccination as an option, preventive antibody products have the advantage of enabling more precise timing of protection in response to RSV activity at the time of birth.

Because RSV vaccination requires administration a minimum of 2 weeks before delivery to be effective, ACOG and CDC recommend against vaccination if delivery is planned or likely within 2 weeks. In such cases, an RSV preventive antibody product should be administered after delivery.

See www.acog.org/clinical/guidance/practice-advisory/2023/09/maternal-respiratory-syncytial-virus-vaccination and https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/pregnant-people.html.

Last reviewed: November 8, 2026

No, only the Pfizer (Abrysvo) RSV vaccine is licensed for use during pregnancy. The GSK RSV vaccine (Arexvy) and the Moderna vaccine (mResvia) are not licensed or recommended for use in pregnancy.

If Arexvy or mResvia is inadvertently administered during pregnancy, do NOT administer a dose of Abrysvo. Instead, CDC recommends that the infant (if younger than 8 months) should be immunized with an RSV preventive antibody product during RSV season (generally October through March in most of the continental United States). Treat the infant in the same manner as an infant born to a mother who did not receive RSV vaccination during pregnancy.

CDC strongly urges that this type of administration error be reported to the Vaccine Adverse Event Reporting System, VAERS (https://vaers.hhs.gov). Prevent administration errors with health care provider training on the different indications for each RSV prevention product (both vaccines and the preventive antibody products for infants) and always check product labels at least three times before administration to verify that the correct product is being administered to the patient. Consider implementing other feasible safeguards in your system (e.g., electronic alerts) to prevent such errors.

Last reviewed: November 8, 2026

Yes, real-world evidence shows that maternal vaccination is effective at preventing infant RSV. One large U.S. study during the 2024-25 RSV season found that maternal vaccination was 49% effective against RSV-associated emergency department (ED) visits and 82% effective against hospitalization. The corresponding effectiveness of nirsevimab RSV preventive antibody product after delivery was 62% against RSV-associated ED visits and 77% effectiveness in preventing hospitalization. See the study at https://doi.org/10.1542/peds.2026-076089.

Last reviewed: November 8, 2026

No. The American College of Obstetricians and Gynecologists (ACOG) and CDC recommend RSV vaccination during pregnancy only for pregnant people who have not previously received an RSV vaccine and who are at the recommended stage of pregnancy (32 weeks through 36 weeks 6 days’ gestation) during the recommended time of year (September 1–January 31 under CDC guidance; September 1–March 1 under ACOG’s 2026–27 guidance). For infants born to mothers who were not vaccinated due to the timing of their pregnancy, history of previous RSV vaccination, or parental preference for use of a preventive antibody product (nirsevimab or clesrovimab) should be administered during or just before the start of their first RSV season and before the age of 8 months 0 days. In regions with seasonal patterns of RSV that differ from the continental United States, such as Alaska, Hawaii, or subtropical parts of Florida, follow state or territorial public health guidance on timing of RSV vaccination or preventive antibody administration, which differ due to differences in RSV seasonality.

Last reviewed: November 8, 2026

Yes. When seasonally appropriate, the American College of Obstetricians and Gynecologists (ACOG) and CDC recommend Pfizer’s RSV vaccine (Abrysvo) for a previously unvaccinated pregnant person from 32 weeks through 36 weeks and 6 days’ gestation. RSV vaccine should not be administered to someone at 37 weeks’ gestation or beyond.

RSV vaccine should be administered at least 2 weeks before delivery to allow time for the maternal immune system to create antibodies and transfer sufficient antibodies to the fetus for adequate protection after birth. If delivery is expected within 2 weeks, plan for the infant to be given RSV preventive antibody protection instead. AAP and CDC recommend that infants born less than 14 days after maternal RSV vaccination should be immunized with an RSV preventive antibody product after birth to ensure adequate protection.

Last reviewed: November 8, 2026


1:44

View All Video Questions

Last reviewed: December 6, 2024

Yes. The American College of Obstetricians and Gynecologists (ACOG) and CDC recommend discussing both options when the timing of pregnancy permits both options to be considered. Those who are previously unvaccinated and between 32 and 36 weeks 6 days’ gestation during CDC’s September–January window (or ACOG’s September 1–March 1 window for 2026–27), may choose to be vaccinated with Abrysvo or have their infant receive an RSV preventive antibody product soon after birth (preferably within the first week of life if born during a month when RSV preventive antibody product administration is recommended).

In some facilities or circumstances, only RSV vaccine or preventive antibody might be available, but not both: those with an option of Abrysvo during pregnancy may not wish to defer that option if, for some reason, they will not have timely access to an RSV preventive antibody product or if they do not wish to administer one. Conversely, if the pregnant person received RSV vaccine before the current pregnancy, only an RSV preventive antibody product administered after birth is recommended for RSV prevention. CDC and AAP recommend that eligible infants younger than 8 months of age whose mothers were not vaccinated receive an RSV preventive antibody product, before or during their first RSV season.

It is important to document the maternal vaccination status and ensure it is available to the healthcare team caring for the infant.

Last reviewed: November 8, 2026


2:15

View All Video Questions

Last reviewed: December 6, 2024

Yes. Under CDC’s VFC program, eligible pregnant adolescents younger than age 19 may receive VFC-funded Abrysvo (Pfizer) RSV vaccine during pregnancy, if indicated, in VFC-participating facilities. Contact your state or territorial immunization program with questions about VFC and Abrysvo.

Last reviewed: November 8, 2026


3:48

View All Video Questions

Last reviewed: June 26, 2026

This page was updated on .